Global Ganja Report

Maryland is expanding its medical marijuana program and adopting policies that attempt to redress the social ills associated with prohibition and the war on drugs—but is meeting resistance both from the police and from elements of the local cannabis industry.

The news that CBD products will be arriving at Walgreens and CVS drugstore chains can be seen as further progress for the normalization of cannabis. But it is also a further indication of corporate control of the new cannabis economy.

Activists in Oregon say that cannabis legalization in the Beaver State has failed to live up to its promise, and are preparing to place a remedy before the voters in the form of a new ballot initiative. They also view their proposed Legalization Justice Act as a model to be exported nationally. 

Legislation introduced in the House of Representatives would protect the jobs of federal employees who use cannabis in states where their use is currently legal. The measure is being hailed by advocates as a critical blow for workers' rights in the age cannabis normalization.

With approval of new regs, Alaska is set to become to the first state to officially oversee cannabis use at licensed retail outlets. Municipalities in Colorado and California have pursued this "Amsterdam model" by working around the state law. But The Last Frontier is once again breaking new ground in personal freedom for cannabis tokers.

The conventional wisdom—and certainly the impression made by much media and advertising—is that CBD is legal pursuant to the federal Farm Bill enacted late last year. As is often the case, however, there are some devils in the details.

As a commercial cannabis industry is established in Jamaica, more Caribbean nations are moving toward decriminalization and establishing medical marijuana programs. Saint Vincent & the Grenadines was the latest to take this move, and it looks like Saint Kitts & Nevis will be next. Dominica and Grenada are studying such proposals, and cannabis tourism is anticipated.

FDA commissioner Scott Gottlieb has suddenly announced that he is stepping down, leaving lots of unfinished business—including the status of CBD under the agency's regs. Biotech stocks are taking a tumble on the news, while tobacco is bullish and cannabis is mixed.